{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:57:57Z","timestamp":1763643477435,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013738","name":"Pacira Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jgar.2022.04.019","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T12:29:35Z","timestamp":1651235375000},"page":"96-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Activity of omadacycline in vitro against Clostridioides difficile and preliminary efficacy assessment in a hamster model of C. difficile-associated diarrhoea"],"prefix":"10.1016","volume":"30","author":[{"given":"Raina Gay","family":"Leahy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-6320","authenticated-orcid":false,"given":"Alisa W.","family":"Serio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria M.","family":"Traczewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Ken","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.04.019_bib0001","unstructured":"Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2019. Available at: https:\/\/www.cdc.gov\/DrugResistance\/Biggest-Threats.html (accessed 8 September 2020)."},{"key":"10.1016\/j.jgar.2022.04.019_bib0002","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical Practice Guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.04.019_bib0003","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1017\/S0950268819000384","article-title":"Modelling diverse sources of Clostridium difficile in the community: importance of animals, infants and asymptomatic carriers","volume":"147","author":"McLure","year":"2019","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jgar.2022.04.019_bib0004","doi-asserted-by":"crossref","first-page":"e00522","DOI":"10.1128\/AAC.00522-20","article-title":"In vitro activity of omadacycline, a new tetracycline analog, and comparators against Clostridioides difficile","volume":"64","author":"Begum","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.04.019_bib0005","doi-asserted-by":"crossref","first-page":"e01581","DOI":"10.1128\/AAC.01581-18","article-title":"Omadacycline gut microbiome exposure does not induce Clostridium difficile proliferation or toxin production in a model that simulates the proximal, medial, and distal human colon","volume":"63","author":"Moura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.04.019_bib0006","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/cix833","article-title":"Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and metaanalysis","volume":"66","author":"Tariq","year":"2018","journal-title":"Clinical Infect Dis"},{"key":"10.1016\/j.jgar.2022.04.019_bib0007","unstructured":"Paratek Pharmaceuticals, Inc. NUZYRA (omadacycline) prescribing information. Revised June 2019. Available at: https:\/\/www.nuzyra.com\/nuzyra-pi.pdf (accessed 8 September 2020)."},{"key":"10.1016\/j.jgar.2022.04.019_bib0008","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/cid\/ciz395","article-title":"Microbiology and preclinical review of omadacycline","volume":"69","author":"Karlowsky","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.04.019_bib0009","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.04.019_bib0010","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O'Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.04.019_bib0011","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O'Riordan","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.jgar.2022.04.019_bib0012","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/cid\/ciz398","article-title":"An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic","volume":"69","author":"Opal","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.04.019_bib0013","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4161\/gmic.19526","article-title":"Models for the study of Clostridium difficile infection","volume":"3","author":"Best","year":"2012","journal-title":"Gut Microbes"},{"key":"10.1016\/j.jgar.2022.04.019_bib0014","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.04.019_bib0015","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.04.019_bib0016","unstructured":"Rodriguez M, Wright K, Noble R. Predicted risk and observed occurrence of Clostridioides difficile infection in patients with community-acquired bacterial pneumonia treated with omadacycline or moxifloxacin. Abstract 5313 at 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2020 (virtual meeting), Abstract book p 2584. Available at: https:\/\/markterfolg.de\/ESCMID\/Abstractbook2020.pdf (accessed 23 June 2021)."},{"key":"10.1016\/j.jgar.2022.04.019_bib0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jinf.2016.04.008","article-title":"Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia","volume":"73","author":"Chalmers","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2022.04.019_bib0018","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.04.019_bib0019","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2022.04.019_bib0020","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cmi.2018.02.013","article-title":"Multicentre derivation and validation of a simple predictive index for healthcare-associated Clostridium difficile infection","volume":"24","author":"Davis","year":"2018","journal-title":"Clinic Microbiol Infect"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522000960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522000960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:00:43Z","timestamp":1761991243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522000960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":20,"alternative-id":["S2213716522000960"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.04.019","relation":{},"ISSN":["2213-7165"],"issn-type":[{"type":"print","value":"2213-7165"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of omadacycline in vitro against Clostridioides difficile and preliminary efficacy assessment in a hamster model of C. difficile-associated diarrhoea","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}